Please use this identifier to cite or link to this item:
標題: 探究新抑癌素蛋白結合穴口底部摺板與生色團之交互作用
Probing the Key Interactions on the Bottom-Strands of Binding Cleft in Neocarzinostatin
作者: 李英賢
李英賢, Ying-Hsien Lee
關鍵字: neocarzinostatin;新抑癌素
出版社: 化學系所
引用: 參考文獻 (Reference) (1) Shen, B., Liu, W., and Nonaka, K., “Enediyne Natural Products: Biosynthesis and Prospect towards Engineering Novel Antitumor Agents.”, Curr. Med. Chem. 2003, 10, 2317–2325 (2) Davies, J.; Wang, H.; Taylor, T.; Warabi, K.; Huang, X. H.; Andersen, R. J. “Uncialamycin, a new enediyne antibiotic.”, Organic Letters 2005, 7, 5233-5236. (3) Kim, K.H., Kwon, B. M., Myers, A. G., and Rees, D. C.,“Crystal Structure of Neocarzinostatin, an Atitumor Protein-Chromophore Complex”, Science, 1993, 262, 1043-1046. (4) Chin, D. -H. “Rejection by protein through charges rather than sizes.” Chem. Eur. J. 1999, 5 (3), 1084-1090. (5) Ishida, N., Miyazaki, K., Kumagai, K., and Rikimaru, M. “Neocarzinostatin, an antibiotic of high molecular weight.”, 1965 J. Antibiotic. (Tokyo) Ser. A 18, 68–76 (6) Hirama, M., Tanaka, T.,“Molecular Recognitionin Neocarzinostatin Complex: how does the apoprotein bind specifically and stabilize the chromophore? ” Pure &Appl. Chem., 1994, 66,791-796. (7) Edo, K., Mizugaki, M., Koide, Y., Seto, H., Furihata, K., Oake, N. & Ishida, N. “The struture of neocarzinostatin chromophore possessing a novel bicyclo-[7,3,0]dodecadiyne system.” Tetrahedron Letters, 1985, 26, 331-334. (8) Maeda, H. “Neocarzinostatin in cancer chemotherapy. ” (Review). Anticancer Res. 1981, 1:175-186 (9) Takahashi, M., Toriyama, K., Maeda, H., Kikuchi, M., Kumagai,K., “Clinical trails of a new antitumor polypeptide: Neocarzinostatin (NCS). ” Tohoku J. Exp. Med. 1969, 98(3), 273-280 (10) Kimura, I., “Clinical investigation of neocarzinostatin in Japan. ” Nippon Ketsueki Gakkai Zasshi, 1974, 37(5), 762-772 (11) Kitajima, K., “The clinical evaluation of a new antileukemic agent. 2) Neocarzinostatin (author’s transl.” Recent Result Cancer Res. 1978, 63, 252-260 (12) Maeda, H., Takeshita, J., Kanamaru, R., “A lopophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic.” Int. J. Pept. Protein. Res. 1979, 14(2), 81-87 (13) Maeda, H., Edo,. N., Ishida, N., “Neocarzinostatin. The past, present, and future of an anticancer drug. Spring-Verlag, Tokyo, 1997, 1-22 (14) Povirk, L. F. & Goldberg, I. H., “Binding of the nonprotein chromophore of neocarzinostatin to deoxyribonucleic acid.” Biochemistry, 1980, 19, 4773-4080. (15) Kappen, L. S. & Goldberg, I. H., “Stabilization of neocarzinostatin nonprotein chromophore activity by interaction with apoprotein and with HeLa cells.” Biochemistry. 1980, 19, 4786-4790. (16) Maeda, H. “SMANCS and polymer-conjugated macromolecular drugs: advantages in cancerchemotheraphy.”, Adv. Drug Deliv. Rev. 2001, 46, 169-185 (17) Mohanty, S., Sieker, L., Drobny, G., “Sequential ''H NMR Assignment of the Complex of Aponeocarzinostatin with Ethidium Bromide and Investigation of Protein-Drug Interactions in the Chromophore Binding Site.”, Biochemistry 1994, 33, 10579-10590 (18) Heyd, B.,Pecorari, F., Collinet, B., Adjadj, E., Desmadril, M., Minard, P., “In Vitro Evolution of the Binding Specificity of Neocarzinostatin, an Enediyne-Binding Chromoprotein. ” Biochemistry 2003, 42, 5674-5683 (19) Chin, D. -H., Zeng, C. H., Costello, C. E. & Goldberg, I. H., “Sites in the diyne-ene bicyclic core of neocarzinostatin chromophore responsible for hydrogen abstraction from DNA.” Biochemistry. 1988, 27, 8106-8114. (20) Edo, K., Katamine, S., Kitame, F., Ishida, N., Koide, Y., Kusano, G., Nozoe, S., “Naphthalenecarboxylic acid from neocarzinostatin (NCS) .” J. Antibiotic. (Tokyo), 1980, 33, 347-351 (21) Schőnberg, G. A., Dewey, R. S., Hensens, O. D., Liesch, J. M., Napier, M. A., Goldberg, I. H., “Neocarzinostatin: chemical characterization and partial structure of the non-protein chromophore .” Biochem. Biophys. Res. Commun. 1980, 95, 1351-1356 (22) Napier, M. A., Goldberg, I. H., Hensens, O. D., Dewey, R. S., Liesch, J. M., Schőnberg, G. A., “Neocarzinostatin chromophore: presence of cyclic carbonate submit and its modification in the structure of other biologically active forms .” Biochem. Biophys. Res. Commu. 1981, 100, 1703-1712. (23) Hensens, O. D., Dewey, R. S., Liesch, J. M., Napier, M. A., Reamer, R. A., Smith, J. L., Schőnberg, G. A., Goldberg, I. H., “Neocarzinostatin chromophore: presence of a highly strained ether ring and its reaction with mercaptan and sodium borohydride .” Biochem. Biophys. Res. Commu. 1983, 113, 538-547 (24) Napier, M. A., Holmquist, B., Strydom, D. J., & Goldberg, I. H. “Neocarzinostatin chromophore: purification of the major active form and characterization of its spectral and biological properties.” Biochemistry. 1981, 20, 5602-5608. (25) Napier, M. A., Holmquist, B., Strydom, D. J., Goldberg, I. H., “Neocarzinostatin: spectral characterization and separation of a non-protein chromophore.” Biochem. Biophys. Res. Commun. 1979, 89, 635-642. (26) Kappen, L. S., Napier, M. A., Goldberg, I. H., “Roles of chromophore and apo-protein in neocarzinostatin action.” Proc. Natl. Acad. Sci. 1980, 77, 1970-1974. (27) Myers, A. G., “Proposed structure of the neocarzinostatin chromophore-methyl thioglycolate adduct; a mechanism for the nucleophilic activation of neocarzinostatin.” Tetrahedron Letters. 1987, 28 (39), 4493-4496. (28) Myers, A. G., Stephen, P. A., and Robert, W. L., “A new and unusual pathway for the reaction of neocarzinostatin chromophore with thiols. Revised structure of the protein-directed thiol adduct.” J. Am. Chem. Soc. 1996, 118, 4725-4726. (29) Sugiyama, H., Yamashita, K., Nishi, M., Saito, I., “A novel cyclization pathway of neocarzinostatin chromophore by thiol under physiological conditions.” Tetrahedron Letters. 1992, 33, 515-518. (30) Jones, R. R., Bergman, R. G., “p-Benzyne. Generation as an intermediate in a thermal isomerization reaction and trapping evidence for the 1,4-benzenediyl structure” Journal of the American Chemical Society., 1972, 94, 660-661. (31) Chin, D. -H., Tseng, M. -C., Chuang, T. -C., Hong, M. -C., “Chromatographic and spectroscopic assignment of thiol induced cycloaromatizations of enediyne in neocarzinostatin.” Biochimica et Biophysica Acta (BBA), 1997,1336, 43–50 (32) Goldberg, I. H., “Mechanism of neocarzinostatin action: Role of DNA microstructure in determination of chemistry of bistranded oxidative damage.” Acc. Chem. Res. 1991, 2, 191-198. (33) Hatayama, T., Goldberg, I. H., Takeshita. M., Grollman, A. P., “ Nucleotide specificity in DNA scission by neocarzinostain.” Proc. Natl. Acad. Sci., 1978, 75(8), 3603-3607 (34) Myers, A. G., Cohen, S. B., & Kwon, B. M., “DNA cleavage by neocarzinostatin chromophore. Establishing the intermediacy of chromophore-derived cumulene and biradical species and their role in sequence-specific cleavage.” J. Am. Chem. Soc. 1994, 116, 1670-1682. (35) Chin, D. -H. & Goldberg, I. H., “Sources of Hydrogen abstraction by activated neocarzinostatin chromophore.” Biochemistry. 1993, 32, 3611-3616. (36) Koide, Y., Ishii, F., Hasuda, K., Koyama, Y., Edo., Katamine, S., Kitame, F., & Ishida, N.“Isolation of a non-protein component from neocarzinostatin (NCS) and their biological activites.” J. Antibiotics, 1980, 33 (3), 342-346 (37) Adjadj E., Quiniou E., Mispelter J., Favaudon V., Lhoste J. M.; "Three-dimensional solution structure of apo-neocarzinostatin from Streptomyces carzinostaticus determined by NMR spectroscopy." Eur. J. Biochem., 1992, 203, 505-511. (38) Adjadj E., Quiniou E., Mispelter J., Favaudon V., Lhoste J. M.; "The seven-stranded beta-barrel structure of apo-neocarzinostatin as compared to the immunoglobulin domain." Biochimie., 1992, 74, 853-858. (39) Nicaise, M., Valerio-Lepiniec, M., Izadi-pruneyre, N., Adjadj, E., Minard, P., Desmadril, N., “Role of the tyrosine corner motif in the stability of neocarzinostatin.” Protein Engineering, 2003, vol. 16, no. 10, 733-738 (40) Meienhofer, J., Maeda, H., Glaser, C. B., Czombos, J., & Kuromizu, K. “Primary structure of neocarzinostatin, an antitumor protein.” Science. 1972, 178, 875-876. (41) Maeda, H., Glaser, C. B., Czombos, J., & Meienhofer, J. “Structure of the antitumor protein neocarzinostatin.” Arch. Biochem. Biophys. 1974, 164, 369-378 (42) Gibson, B. W., Herlihy, W. C., Samy, T. S., Hahm, K. S., Maeda, H., Meienhofer, J., Miemann, K. A., “A revised primary structure for neocarzinostatin based on fast atom bombardment and gas chromatographic mass spectroscopy.” J. Biol.Chem., 1984, 259, 10801-10806 (43) Kuromizo, K., Tsunasawa, S., Maeda, H., Abe, O., Sakiyama, F., “Reexamination of the primary structure of an antitumor protein, neocarzinostatin.” Arch. Biochem. Biophys., 1986, 246, 199-205 (44) Sakata, N., Minamitani, S., Kanbe, T., Hori, M., Hamada, M., & Edo, K., “The amino acid sequence of neocarzinostatin apoprotein deduced from the base sequence of the gene.” Biol. Phar. Bull. 1993, 16, 26-28. (45) Remerowski, M. L., Glaser, S. J., Sieker, L. C., Samy, T. S., Drobny, G. P., “Sequential 1H NMR assignments and secondary structure of aponeocarzinostatin in solution. Biochemistry.” 1990, 29(36), 8401-8409 (46) Adjadj E., Mispelter J., Quiniou E., Dimicoli, J. L., Favaudon V., Lhoste J. M.; "Proton NMR studies of apo-neocarzinostain from Streptomyces carzinostaticus. Sequence-specific assignment and secondary structure.” Eur. J. Biochem. 1990, 190(2), 263-271 (47) Gao, X. L., Burkhart, W.; "Two- and Three-dimensional proton NMR studies of apo-neocarzinostatin.” Biochemistry, 1991, 30(31), 7730-7739 (48) Gao, X. L., " Three-dimensional solution structure of apo-neocarzinostatin.” Mol. Biol.,1992, 225(1), 125-135 (49) Lefevre, C., Adjadj E., Quiniou E., Mispelter J., "Assignment of the protonated 13C resonances of apo-neocarzinostatin by 2D heteronuclear NMR spectroscopy at natural abundance.” J. Biomol. NMR., 1994, 4(5), 689-702 (50) Mispelter J., Lefevre, C., Adjadj E., Quiniou E., Favaudon V., "Internal motions of apo-neocarzinostatin as studies by 13C NMR methine relaxation at natural abundance.” J. Biomol. NMR., 1995, 5(3), 233-244 (51) Tanaka, H., Hirama, M., Ueno, M., Imajo, S., Ishiguro, M., Mizugaki, M., Edo, K., Komatsu, H., “Proton NMR studies on the chromophore binding structure in neocarzinostatin complex.”, Tetrahedron Lett., 1991, 32, 3175 (52) Takashima, H., Amiya, S., Kobayashi, Y., “Neocarzinostatin: Interaction between the Antitumor-Active Chromophore and the Carrier Protein.”, J. Biochem., 1991, 109,807-810. (53) Imajo, S., Ishiguro, M., Tanaka, T., Hirama, M., Teplyakov, A., “On the conformation of Phe78 of a chromoprotein antibiotic, neocarzinostatin.” Bioorg Med Chem., 1995, 3(4), 429-436 (54) Kappen, L. S., Goldberg, I. H., “Mechanism of the effect of organic solvents and other protein denaturants of neocarzinostatin activity.” Biochemistry. 1979, 18, 5647-5653. (55) Urbaniak, M., Muskett, F., Finucane, M., Caddick, S., Woolfson, S., “Solution Structure of a Novel Chromoprotein Derived from Apo-Neocarzinostatinand a Synthetic Chromophore.” Biochemistry 2002, 41, 11731-11739 (56) Valerio-Lepiniec,M., Nicaise, M., Adjadj,E., Minard, P., Desmadril, M., “Key interactions in neocarzinostatin, a protein of the immunoglobulin fold family. ” Protein Engineering, 2002, vol.15, no.11 pp.861–869. (57) Jayachithra, K., Kumar, T. K. S., Lu, T. J., Yu, C., Chin, D. H., “Cold Instability of Aponeocarzinostatin and its Stabilization by Labile Chromophore. ”, Biophysical Journal, 2005, 88, 4252–4261 (58) Tanaka, T., Hirama, M., Fujita, K.I.,. Imajo, S., Ishiguro, M., “Solution Structure of the Antitumor Antibiotic Neocarizinostatin, a Chromophore-Protein Complex. ” J. CHEM. SOC., CHEM. COMMUN., 1993, 1205-1207 (59) Takashima, H, Yoshida, T., Ishino, T., Hasuda, K., Ohkubo, T., Kobayashi, Y., “Solution NMR Structure Investigation for Releasing Mechanism of Neocarzinostatin Chromophore from the Holoprotein. ”. J. Biological Chemistry, 2005, Vol. 280, No. 12, 11340–11346. (60) Hariharan, P., Liang, W. C., Chou, S. H., Chin, D. H., “A New Model for Ligand Release Role of Side Chain In Gating the Enediyne Antibiotic. ”JBC, 2006, 281(23), 16025–16033. (61) Nicaise, M., Valerio-Lepiniec, M., Izadi-pruneyre, N., Adjadj, E., Minard, P., Desmadril, M., “Role of the tyrosine corner motif in the stability of neocarzinostatin. ”, Protein Engineering, 2003, 16(10) 733-738 (62) Metthews, B. W., “Structural and genetic analysis of the folding and the function of the T4 lysozyme.”, FASEB, 1996, 10, 35-41 (63) Strub, C., Alies, C., Lougarre, A., Ladurantie, C., Czaplicki, J., Fournier, D., “Mutation of exposed hydrophobic amino acids to arginine toincrease protein stability .”, BMC Biochem, 2004, 5:9, 1-6
生色團與新抑癌素蛋白結合時,生色團上的萘環(naphthoate moiety)位於新抑癌素蛋白疏水性結合穴口的底部,是生色團與新抑癌素蛋白緊密結合不可或缺的部份,另外,此萘環和穴口底部的胺基酸殘基有許多特定的交互作用;這些交互作用是新抑癌素蛋白能與生色團結合並具穩定生色團功能的要素。
為探討新抑癌素蛋白穴口底部的胺基酸殘基對結合生色團的影響,我們利用定點突變技術製造突變質體DNA,轉殖入大腸桿菌後大量表現所需的突變蛋白;以下四個新抑癌素蛋白殘基V34,Q36與Q94,L97分別兩兩位於構成新抑癌素蛋白穴口底部的兩個不同β摺板中,其骨架或側鏈與生色團上萘環相距不遠,我們檢驗生色團釋放速率是否因此突變而改變,以便探討蛋白與生色團結合強度是否因突變而改變。由大腸桿菌大量表現且純化後的突變蛋白V34A、Q36A、Q94A和L97A,以質譜儀鑑定分子量無誤且雙硫鍵均完整存在,以圓二色光譜儀(Circular Dichroism)證明它們的二、三級結構與新抑癌素蛋白相似,我們並比較突變蛋白和新抑癌素蛋白的熱穩定性。之後用純化的重組突變蛋白與淬取的生色團再結合形成複合體,利用螢光光譜儀分析比較突變蛋白與新抑癌素蛋白釋放生色團速率的差異,本研究結果顯示突變蛋白V34A釋放生色團的速率大幅提高,推測這特定蛋白殘基大幅影響生色團結合的強度;而L97A蛋白釋放生色團速率與天然新抑癌素接近。

Neocarzinostatin, a natural and potent antitumor antibiotic chromoprotein complex, is composed of an all β-sheet protein (aponeocarzinostatin) and a labile enediyne containing chromophore. Aponeocarzinostatin acts as a carrier and protector of the bioactive chromophore and plays crucial roles in regulating availability of the chromophore. Released chromophore can be activated by thiols in vivo and in vitro after which, diradical intermediate is formed via Bergman cycloaromatization. To perform its cytotoxic function, the radical intermediate abstracts hydrogen from deoxyribose backbone to cause DNA damages in the presence of oxygen.
Specific intermolecular interactions between the chromophore and aponeocarzinostatin, in particular those amino acid residues at the bottom of the binding pocket of aponeocarzinostatin, underlie the binding and stabilization of the labile chromophore. How the non-covalent interactions between protein and its chromophore lead to very tight binding (KD ≤ 0.1 nM) raises an interesting question. Therefore, understanding the interaction of the chromophore with individual residues in the protein binding pocket is crucial for such investigation.
In the present study, we employed alanine scanning mutagenesis on four amino acid residues (V34, Q36, Q94 and L97) located in different β-sheet strands at the bottom of the binding pocket of aponeocarzinostatin. To investigate their contribution to the overall strength of binding interactions, a PCR-based in vitro site-directed mutagenesis was adapted to produce mutant protein expression constructs. Mutant recombinant aponeocarzinostatin (V34A, Q36A, Q94A and L97A) proteins were expressed in E. coli followed by purification involving various chromatographic techniques. Purified mutant proteins were subjected to circular dichroism spectroscopic studies to analyze secondary and tertiary structures. Structural stability of the mutant proteins is investigated by thermal denaturation experiment monitored by circular dichroism. Reconstituted holoneocarzinostatin for each mutant was prepared by titrating each mutant protein with 1:1 molar ratio of the extracted chromophore. Influence of mutant proteins on the binding interactions was studied by examining release rate of the chromophore. Fluorescence analysis of chromophore release kinetics reveals that the release rate of V34A is significantly higher than that of wild-type neocarzinostatin. Mutant L97A had similar release rate as that of the wild-type neocarzinostatin. Chromophore release trend among the mutants was further confirmed by HPLC analysis.
The results offer some clues for understanding specific role of some residues at the bottom of binding cleft in intermolecular interactions between aponeocarzinostain and its chromophore.
其他識別: U0005-2512200710563501
Appears in Collections:化學系所

Show full item record
TAIR Related Article

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.